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Purpose: The prognoses of seizure treatment with P450 enzyme-inducing and non-enzyme-inducing
antiepileptic drugs after glioma resection surgery were investigated across several clinical studies.
However, the results of these studies are inconsistent. We examined the relevant studies and conducted
a meta-analysis of these two types of anti-epileptic drugs.
Methods: A bibliography search using the EMBASE, MEDLINE, ClinicalTrials.gov, and Cochrane Central
Register of Controlled Trials databases was performed to identify potentially relevant articles and
conference abstracts that investigated the effects of non-enzyme-inducing antiepileptic drugs (NEIAEDs)
and enzyme-inducing antiepileptic drugs (EIAEDs) on the seizure prognoses of glioma patients.
Results: One RCT study and ﬁve observational studies were included. Pooled estimates of the relative
risks (OR) and 95% conﬁdence intervals (CI) were calculated. The pooled odds ratio for NEIAEDs vs.
EIAEDs for patients with glioma was 1.12 (95% CI = 0.70–2.10). The pooled odds ratio for NEIAEDs vs.
EIAEDs for low-grade gliomas was 1.77 (95% CI = 0.71–4.40). The pooled odds ratio for LEV vs. PHY was
1.459 (95% CI = 0.731–2.910).
Conclusions: No signiﬁcant difference between the efﬁcacies of P450 enzyme-inducing and non-
enzyme-inducing antiepileptic drugs for prophylactic late seizure treatment was observed. However,
few RCTs were available, and the acquisition of further evidence through high-quality RCTs is highly
recommended.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Glioma is the most frequent and deadliest primary malignant
brain neoplasm in humans and accounts for more than 40% of all
adult brain tumors.1 The WHO has categorised four major grades of
gliomas, and one of the most common symptoms of these tumours
is epilepsy.2 Although gross-total resection is an effective control
measure for glioma-related epileptic activity, approximately 30%
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reachieve satisfactory seizure prognoses,3 which signiﬁcantly affects
the glioma patients’ quality of life and makes it difﬁcult for these
patients to return to work and society. Thus, glioma-associated
epilepsy (GAS) is an important clinical issue that requires the care
of neurosurgeons. Nonetheless, the medical treatment of these
seizures is often met with limited success due to the currently
incomplete understanding of their aetiology. Surprisingly, at
present, there are no speciﬁc GAS guidelines to aid neurosurgeons
in prescribing antiepileptic drugs (ADEs) for post-surgery glioma
patients; instead, the choice of prescriptions is based on the
neurosurgeons’ personal preferences and clinical experiences.
Enzyme-inducing antiepileptic drugs (EI-AEDs), such as phe-
nytoin and carbamazepine, remain the ﬁrst-line AEDs prescribed
by neurosurgeons for the control of GAS; however, the side effects
have been reported to occur with high incidence.4 Phenytoin and
carbamazepine are potent inducers of six major human P450
microsomal enzymes (i.e., CYP 1A2, 2C9, 2C19, 2D6, 2E1, and 3A4),
and this activity may accelerate the metabolism of chemother-
apeutics and molecularly targeted agents, which may, in turn, helpserved.
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AEDs are not metabolised by the P450 system and may involve
other unexpected interactions that do not involve known path-
ways; hence, recent articles favour the use of valproic acid or
newer anticonvulsants, such as lamotrigine and levetiracetam,
over the use of carbamazepine and phenytoin.7
Phenytoin, carbamazepine, sodium valproate, and levetirace-
tam are the most frequently used AEDs in clinical settings for the
treatment or prevention of seizure activity in post-surgery glioma
patients. Furthermore, the co-administration of AEDs and
chemotherapy agents is often recommended by neurosurgeons.8
The effectiveness of EI-AEDs compared to that of non-EI-AEDs in
the treatment of epilepsy in glioma patients in uncertain. Many
clinical trials have produced various results regarding the
effectiveness of these two types of drugs. Tracey and his
colleagues noted that both levetiracetam (LEV) and phenytoin
(PHY) are associated with a low risk of early postoperative
seizures and a moderate risk of later epilepsy.9 In contrast, a
randomised controlled trial reported better long-term outcomes
with LEV after neurosurgical injury compared with phenytoin.10
To the best of our knowledge, even though the answer to this
question is important for patients requiring chemotherapy, the
available research studies that compared the efﬁcacies of EI-AED
and non-EI-AEDs for the treatment of post-surgery glioma
patients have not been systematically analysed.
With the aim of summarising the evidence on P450 enzyme-
inducing and non-enzyme-inducing antiepileptic drugs in the
prophylactic treatment of seizures according to multiple tumour
sub-types, we combined and analysed all of the published data
using a meta-analytic approach.
2. Methods
2.1. Search strategy
In October 2013, a bibliography search of the EMBASE,
MEDLINE, ClinicalTrials.gov, and Cochrane Central Register of
Controlled Trials databases was conducted to identify potentially
relevant articles and conference abstracts that compared the
effects of P450 enzyme-inducing and non-enzyme-inducing
antiepileptic drugs in the prophylactic treatment of seizures after
glioma resection surgery. Because enzyme-inducing and non-
enzyme-inducing AEDs are two large, dichotomous classes of
drugs, we selected the four AEDs that are most frequently used as
prophylactics for glioma-associated seizures (i.e., phenytoin,
carbamazepine, sodium valproate, and levetiracetam). The search
was limited to studies written in English. Two investigators (Y.Y
and M.YH) independently evaluated the papers according to the
inclusion and exclusion criteria, and any controversies were settled
by discussion and consensus. The references contained in the
identiﬁed trials were also examined to identify any other relevant
published or unpublished articles. We used combinations of the
following search terms: phenytoin, carbamazepine, sodium
valproate, levetiracetam, glioma, and brain tumour (details of
the search rules are provided in Supplemental ﬁle 1).
2.2. Inclusion and exclusion criteria
The inclusion criteria were the following:
(a) Because drug use may involve ethical issues and limited RCTs,
all comparative studies (i.e., trial, cohort, case-control, and
observational studies) of the relevant ADEs were included;
(b) The glioma cases were histological conﬁrmed, and all of the
included patients had undergone surgery;(c) The articles provided post-surgery seizure outcomes, and the
data included at least the seizure activity records after surgery.
The agreed minimum length of the follow-up period should be
at least 6 months; and
(d) The odds ratios (ORs) or relative risks (RRs) and the 95%
conﬁdence intervals (CIs), or sufﬁcient raw data to calculate
these variables, were provided.
We excluded studies for the following reasons:
(i) The RR and/or OR data were not available or insufﬁcient to
conduct a meta-analysis;
(ii) The patients had only received a biopsy or chemotherapy; and
(iii) The article type was a letter, editorial, or review.
2.3. Data extraction
The ﬁrst two authors (Y.Y. and M.YH) extracted the following
data from each eligible article using a standardised form. Any
disagreements were resolved through discussion or consultation
with another author (M.Q.). The study designs, patient character-
istics, operational deﬁnitions, seizure outcomes, ORs, RRs, and 95%
CIs were extracted from the articles. We also sent emails to the
corresponding authors requesting any missing information as
appropriate.
3. Statistical analyses
Our primary outcome was the efﬁcacy of seizure control. We
conducted meta-analyses when data were available from more
than one study. The odds ratios (ORs) or risk ratios (RRs) with the
95% conﬁdence intervals presented in the studies were used to
estimate the pooled risk. The heterogeneities of the studies were
assessed using the Cochran’s Q statistic and the I2 statistic. When
the p value was at most 0.1 and the I2 value was greater than 50%,
the heterogeneity was considered signiﬁcant. Publication biases
were estimated using Egger’s tests, and p values less than 0.005
were considered evidence of publication bias. All of the p values
were two-sided, and all of the analyses were performed using
STATA version 11 (STATA/SE, College Station, TX).
Because the characteristics of the eligible patients, study
designs, glioma malignancy levels, and adjustments for confound-
ing factors were not consistent across the articles, we performed
further subset and sensitivity analyses to explore all possible
explanations for this heterogeneity and to assess the potential
effects of these variables on the outcomes.
4. Results
4.1. Search results and study characteristics
Fig. 1 shows the ﬂow diagram of the electronic literature search
and the selection of articles. A total of 8538 unique publications
were identiﬁed after the exclusion of duplicates, and the titles or
abstracts of these articles were examined to exclude the unrelated
studies. Ultimately, 172 relevant articles were identiﬁed as
primary studies, and the full texts of these articles were retrieved.
We then identiﬁed eight studies as eligible for our meta-analysis.
The authors of these studies were contacted for further informa-
tion if the data presented in the article was insufﬁcient for our
needs. The meta-analysis was ultimately based on six studies (ﬁve
observational and 1 RCT; this information is summarised in
Table 1).4,9,11–14 Four of the studies were conducted in North
America, one was conducted in Asia, and one was conducted in
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Fig. 1. Flow diagram of the electronic literature search and the selection of articles.
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Christopher et al. (2013) were excluded to limit the amount of
data15,16 (See Table 2).
Table 1 displays the characteristics of the six studies that were
included in our meta-analysis. Overall, the majority of the 845
patients who were included had been diagnosed with glioma
(WHO grade II–IV), and the patients had most commonly been
diagnosed with WHO grade II glioma. The largest cohort study wasTable 1
Summary of studies included in the meta-analyses.
Study Country Study
design
No. of
patients
ADEs (dosage/
Daniel et al. (2009)4 USA RCT 23 LEV (1000–300
PHY(300–400 m
Merr ell et al. (2010)11 USA Obs 76 LEV(NA)
PHY(NA)
Rosati et al. (2009)12 Italy Obs 22 LEV (1500–400
PHT (200–400
CBZ (800–120
Edward et al. (2009)13 USA Obs 224 PHT(NA)
CBZ(NA)
VPA(NA)
Tracey et al. (2008)9 USA Obs 55 PHT(NA) LEV(N
Gan You et al. (2012)14 CHINA Obs 445 VPA(NA)
PHT(NA)
CBZ(NA)
Obs, observational study; RCT, randomised controlled trial; LEV, Levetiracetam; PHY, pconducted by Gan et al. and included 445 WHO grade II glioma
patients.
4.2. Outcomes
The follow-up period of all of the studies was at least six
months. Our analysis demonstrated that neither non-EIAEAs nor
EIAEDs exhibited superior seizure prophylaxis after glioma
resection surgery. The pooled odds ratio was 1.12 (95%
CI = 0.70–2.10, heterogeneity p = 0.420, I2 = 0.0%). We also con-
ducted a subset analysis of the studies according to the high- and
low-grade glioma malignancy levels. However, most of the studies
only reported the relative seizure control rates of the different
drugs (e.g., LEV vs. PHY or VPA vs. PHY) and did not report the
tumour histology. Therefore, we could not extract sufﬁcient data to
conduct a subset analysis of high-grade gliomas. The pooled odds
ratio for non-EIAEDs vs. EIAEDs as seizure prophylaxes for low-
grade gliomas was 1.77 (95% CI = 0.71–4.40, p for heterogene-
ity = 0.982, I2 = 0.0%); thus, the difference in the seizure control
efﬁcacies of NEIAEDs and EIAEDs for the treatment of patients with
low-grade gliomas also failed to reach signiﬁcance. We also
conducted an analysis of LEV vs. PHY based on data from four
studies. No signiﬁcant heterogeneity was detected (p for hetero-
geneity = 0.430, I2 = 0.0%), and the pooled odds ratio between the
two AEDs was 1.459 (95% CI = 0.731–2.910).
No signiﬁcant asymmetries in the funnel plots were found in
our analysis, which suggests the absence of publication bias, and
the tests for publication bias produced p values greater than 0.25.
However, these analyses were limited by the low number of
studies (Figs. 2–4).
5. Discussion
In the present study, we systematically reviewed the relevant
data and conducted a meta-analysis to determine whether P450
enzyme-inducing antiepileptic drugs control seizures more
effectively than non-P450 enzyme-inducing antiepileptic drugs
in glioma patients after surgery. We demonstrated that NEIAEDs
and EIAEDs were not different in terms of their efﬁcacies as seizure
prophylaxis.
Seizure prevention and treatment have long been important
services provided by neurosurgical units. The problems associated
with seizure prevention and treatment are complex, and neuro-
surgeons should consider the interactions between antiepileptic
and anticancer agents, the efﬁcacy and side effects of antiepileptic
drugs, the mechanisms of antiepileptic drugs, etc. Two previous
meta-analyses have suggested that phenobarbital, phenytoin, andday) Glioma pathology Seizures
assessed at
Risk estimate (95% CI)
NEIAED vs. EINED
0 mg)
g)
WHO grades I–IV 6 months 2.167(0.244–19.276)
WHO grades II–IV 6–96 months 0.952(0.359–2.526)
0 mg)
 mg)
0 mg)
WHO grades II–IV 3.2 years 13.000(0.628–268.926)
WHO grade II 6–12 months 1.887(0.388–10.592)
A) Not clear At least 1 year 1.440(0.382–5.428)
WHO grade II 6–12 months 0.582(0.198–1.711)
henytoin; CBZ, carbamazepine; VAP, valproic acid; NA, not available.
Table 2
Reasons of studies excluded in the meta-analysis.
Study Country Study
design
No. of
patients
ADEs (dosage/day) Glioma
pathology
Reasons for study exclusion
Diego Garbossa et al.15 Italy Obs 143 LEV(1000 mg) WHO grades
III–IV
The study design was Levetiracetam
(LEV) vs. No AED as prophylaxis. Not
met our inclusion criteria
Christopher16 USA Obs 544 PHT(NA) LEV(NA)
VPA(NA) CBZ(NA)
GBM No seizure history records before surgery,
ORs could not obtained from raw data
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tumours, but no speciﬁc meta-analysis of glioma patients had been
previously conducted.17,18
Phenytoin, carbamazepine, sodium valproate, and levetira-
cetam are the AEDs that are most frequently used and studied by
neurosurgeons, and these drugs are EIAEDs and NEIAEDs.
Valproic acid (VPA) is one of the most-studied non-EIAEDs that
are used to treat glioblastoma multiforme. VPA has been studied
in vivo, in vitro and in clinical studies; however, the mechanisms
underlying the possible beneﬁts of VPA are not clear. Temozo-
lomide is a prodrug and an imidazotetrazine derivative of the
alkylating agent dacarbazine; the drug-to-drug interaction
between VPA and temozolomide may reduce the clearance of
temozolomide, which may increase its bioavailability or induce
autophagy in vivo.19 Another potential beneﬁt of VPA may be due
to its action as a histone deacetylase (HDAC) inhibitor.20 As a
HDAC-inhibiting agent, valproic acid may enhance the sensitivity
of tumour cells to chemotherapy, induce growth arrest, induce
the differentiation or apoptosis of glioma cells, and improve the
survival of patients when combined with one or more
chemotherapeutic agents. Weller et al. reported that patients
receiving VPA alone (97 [16.9%]) appear to derive more survival
beneﬁt from TMZ/RT (hazard ratio [HR] 0.39, 95% conﬁdence
interval [CI] 0.24–0.63) than patients receiving an EIAED alone
(252 [44%]) (HR 0.69, 95% CI 0.53–0.90) and patients who are not
receiving any AED (HR 0.67, 95% CI 0.49–0.93).21 Another equally
intriguing ﬁnding is the autophagy stimulated by valproic acid.
Autophagy represents an alternative tumour-suppression mech-
anism that overcomes the strong resistance of malignant gliomas
to radiotherapy and proapoptotic-related chemotherapy.22Fig. 2. Forest plot of the studieLevetiracetam (UCB Pharma, Inc.) is known as a second-
generation AED and has been used to control seizures in patients
with glioma. The mechanism underlying the anti-epileptic effect
of LEV remains unclear, and most of the relevant studies have
been conducted in clinical settings. With respect to seizure
prophylaxis, Merr ell et al. found that levetiracetam and
phenytoin have similar seizure control efﬁcacies when used to
treat patients with glioma.23 Lim et al. also found no signiﬁcant
differences between levetiracetam and phenytoin in a random-
ised phase II pilot study.4 Previous research has also shown that
both VPA and LEV appear to have beneﬁcial effects on verbal
memory and limited side effects in glioma patients.24 A number
of investigators have also demonstrated that the serial monitor-
ing of LEV is not required. Other non-EIAEDs, such as lamotrigine,
have been less frequently used and studied in glioma patients.
Phenytoin (PHY) and carbamazepine are considered to be the
old generation of anti-epileptic drugs compared with newer anti-
epileptic drugs because they are not metabolised by the hepatic
P450 system.7 For decades, phenytoin has been the ﬁrst choice for
the control of glioma-related seizures (GAS) in many hospitals.
Both phenytoin and carbamazepine are potent inducers, and the
serum levels of many chemotherapeutic drugs, such as irinotecan,
topotecan, teniposide, and thiotepa, may be signiﬁcantly reduced
by PHY or carbamazepine.25 Moreover, corticosteroid metabolism
is highly sensitive to enzyme induction. EIAEDs increase the
metabolism of various steroids, which may lead to insufﬁcient
control of peritumoural edema.26 Most of the side effects of
phenytoin are well tolerated, and the most common side effects are
rash, drowsiness, dizziness, and hirsutism.27 The most feared side
effect of phenytoin is Stevens-Johnson syndrome.28s on post-surgery seizures.
Fig. 3. Forest plot of the studies on post-surgery seizures in patients with low-grade gliomas.
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between EIAEDs and NEIAEDs in terms of seizure control. The
pooled odds ratio for NEIAEDs vs. EIAEDs was 1.12 (95% CI = 0.70–
2.10) in patients with glioma, which means that the seizure
activity occurrence rate in the NEIAED group was 1.12-fold higher
than that of the EIAED group. However, taking a = 0.05 as the
examination standard, this difference shows no statistical signiﬁ-
cance. However, the intriguing abovementioned results raise the
question of whether non-P450 enzyme-inducing antiepileptic
drugs, particularly LEV and VPA, should be routinely used to
control seizures or prolong the lives of glioblastoma patients. The
answer requires more information and careful consideration. Most
of the results discussed were generated through unplanned
retrospective analyses. The selection of the AEDs that were used
depended on the investigators’ preferences and local practices,Fig. 4. Pooled risk estimates and 95% conﬁdence intervals for the associaalthough we did not ﬁnd any evidence of bias. However, non-
EIAEDs do have advantages in the treatment and prophylaxis of
seizures in high-grade glioma patients. Non-EIAEDs do not affect
anticancer agents when used as adjuvant treatments, and valproic
acid may even elevate the plasma concentrations and toxic bone
marrow effects of concomitant chemotherapeutic drugs. Non-
EIAEDs have been reported to induce fewer side effects. Moreover,
the metabolism of the corticosteroids that are frequently used to
control brain oedema is not increased by non-EIAEDs. Fortunately,
additional data concerning this question may be available soon
from a recently completed Radiation Therapy Oncology Group
phase III trial (RTOG 0525) that compared the standard adjuvant
temozolomide with a dose-dense regimen and from phase II trials
of VPA (NCT00302159) and the HDAC inhibitor vorinostat
(NCT00731731) with radiation therapy and temozolomide fortion between the efﬁcacies of LEV and PHY as seizure prophylactics.
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await the results of these international RCTs and hope that the
results of these studies will enhance the treatment of glioblasto-
ma-associated seizures. Additionally, more research studies on LEV
need to be conducted.
We initially planned to perform a meta-analysis of glioma
seizure prophylaxes and sought to evaluate the roles of non-
EIAEDs and EIAEDs in the treatment of low- and high-grade
gliomas. Compared with low-grade gliomas, GBMs and high-
grade gliomas more frequently require chemotherapy, and we
sought to examine the differences between NEIAEDs and EIAEDs
in patients who had undergone standard chemotherapy.
However, the available literature failed to provide adequate
data for the conduction of sub-analyses of high-grade glioma or
GBM despite our best efforts to contact the corresponding
authors of all of the relevant papers. We also found that few
RCTs have compared these two types of drugs. Thus, we
recommend that more RCTs on this topic be performed. Because
four of the six eligible studies found included comparisons
between LEV and PHY, a sub-analysis of the differences between
these two drugs was performed, and no signiﬁcant difference in
seizure prophylaxis was found.
6. Conclusions
The results of our study suggest that there is no signiﬁcant
difference between the efﬁcacies of P450 enzyme-inducing and
non-enzyme inducing antiepileptic drugs for late seizure prophy-
laxis. The sub-analysis revealed the following: (i) NEIAEDs and
EIAEDs are not different in terms of seizure control in post-surgery
patients with low-grade gliomas and (ii) levetiracetam and
phenytoin exhibit similar seizure control efﬁcacies. Further RCTs
on this subject should be performed.
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